Zepbound became the first drug approved by the Food and Drug Administration to treat obstructive sleep apnea in obese adults earlier this month. “This is a major step forward for patients with obstructive sleep apnea,

The FDA on Friday approved Eli Lilly's weight-loss drug Zepbound as a treatment for moderate-to-severe sleep apnea and obesity.

The Food and Drug Administration (FDA) announced the approval of the weight loss drug Zepbound, generically known as tirzepatide, to help people treat obstructive sleep apnea.

Zepbound is the first prescription drug approved specifically to treat the common condition. The Food and Drug Administration on Friday approved the weight loss drug Zepbound to treat obstructive sleep apnea. It is the first prescription medication approved to treat the common sleep disorder.

The agency’s decision expands the use of Zepbound and could potentially pave the way for Eli Lilly to gain broader insurance coverage for the treatment.

The Food and Drug Administration on Friday approved Eli Lilly’s weight-loss drug Zepbound to treat sleep apnea, a common but potentially serious sleep-related breathing disorder, marking the first medication for certain patients with the condition.

The Food and Drug Administration (FDA) approved a weight-loss drug to help sleep apnea, becoming the first drug to treat the disorder affecting millions of Americans. On Friday, the federal agency green-lighted Eli Lilly’s Zepbound drug for the use,

The FDA said studies have shown that by aiding weight loss, Zepbound improves sleep apnea symptoms in some patients.

The drug is known as Zepbound and is the same as the chemical drug Tirzepatide. "See To Believe uncovers the forgotten, mind-blowing facts that will leave you questioning everything. Follow wild stories of mysterious creatures,

Zepbound, a drug approved by the FDA, has been shown to reduce the severity of obstructive sleep apnea in obese adults, although it is not a cure and requires weight loss to be maintained over time.